High-intensity chemotherapy versus palliative chemotherapy in patients over 60 years with acute myeloid leukemia

• Published in: Revista médica (Mexico : 1983) Vol. 54 Suppl 2; p. S148
• Main Authors: Medrano-Contreras, Jesús, Talavera-Piña, Juan Osvaldo, Guerrero-Rivera, Susana, Gutiérrez-Espíndola, Guillermo Rodolfo, Gómez-Cortés, Cynthia, Pérez-Rocha, Juan Fernando, Terreros-Muñoz, Eduardo, Meillón-García, Luis Antonio
• Format: Journal Article
• Language: Spanish
• Published: Mexico 2016
• Subjects: Aged; Aged, 80 and over; Anthracyclines - therapeutic use; Antineoplastic Agents - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Cytarabine - therapeutic use; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute - drug therapy; Leukemia, Myeloid, Acute - mortality; Male; Middle Aged; Palliative Care - methods; Retrospective Studies; Treatment Outcome; Chemotherapy; Acute myeloid leukemia; Elderly
• ISSN: 0443-5117

The use of high-intensity chemotherapy (HIC) for acute myeloid leukemia (AML) in the elderly is controversial. In the present study, it was assessed complete remission and overall survival of AML patients over 60 years treated with HIC or palliative chemotherapy.
Patients with ECOG ≤ 2 and adequate organic function received HIC with a base of cytarabine for five or seven days, and an anthracycline for three days. If patients achieved complete remission of leukemia, they received one or two cycles of consolidation with cytarabine. Palliative treatment consisted of supported measures and/or oral or intravenous low-dose chemotherapy.
Seven patients treated with HIC achieved complete remission versus only one in the palliative group. Only one patient died during HIC treatment. Median survival for HIC-treated patients was 13.25 months, and only 3.35 months for patients treated with palliative therapy (p < 0.05).
AML patients of 60 years or older, with good performance status (ECOG ≤ 2) and adequate organ function, may benefit from HIC treatment, with better survival, compared with palliative therapy.